Executive Director Kyung-ik Lee, DXVX New Drug Research Headquarters.
DXVX is transforming itself into an artificial intelligence (AI)-based new drug development company.
DXVX is currently conducting an AI-based new drug development project centered around Lee Kyung-ik, Executive Director and expert in new drug modeling (Ph.D. in physical chemistry). At the same time, the company is evolving into an AI-based new drug development firm through the digital transformation of its existing genomic data.
Lee Kyung-ik, who recently joined the new drug research headquarters, is a former senior researcher at Hanmi Pharmaceutical and an expert in AI modeling-based new drug development with experience in all research fields from structure to computation and synthesis. Through diverse experiences such as chemical synthesis and protein expression, he possesses expertise and know-how in designing actual molecules.
He notably laid the foundation for Korea’s improved drug business with the development of “Amlodipine camsylate.” Additionally, he led the optimization of various synthetic drugs through computer-aided drug design (CADD) and made significant contributions to the development of 5’-capping and lipid nanoparticle (LNP) processes, which are core technologies for mRNA-based vaccines and therapeutics. Furthermore, he has achieved results in rare disease treatments and anticancer drugs at Youngjin Pharm.
DXVX is actively promoting innovative new projects as well as optimizing AI-utilized new drug candidates centered around Executive Director Lee Kyung-ik.
Moreover, by recently recruiting Song Ki-young, a 20-year veteran IT expert, as head of the IT planning team, DXVX is advancing the digital transformation and commercialization of its medical data assets. Song Ki-young has rich practical experience, having served as head of Nexon’s China branch and worked on AI-based medical software planning at Tencent, among others. He has completed the formation of an IT expert group including front-end and back-end developers, leading DXVX’s digital transformation.
DXVX plans to soon launch services for the advancement and commercialization of a medical information platform through AI-based digital database system conversion, centered on the IT planning team. This medical information platform will expand as a B2B service targeting new drug developers and hospitals requiring specific genomic information. DXVX holds the largest domestic clinical genomic analysis data with over 400,000 cases.
A DXVX official stated, “AI-based services are becoming a new trend in the medical market. Currently, we are operating various new drug development projects and are increasing the success potential of new drug development by utilizing artificial intelligence (AI) in each area, while expanding related services.”
Meanwhile, DXVX is participating in clinical trials for metabolic diseases such as obesity and diabetes conducted by its affiliate Coriitaly and Gemelli Hospital. It is also reviewing license-in opportunities for Oxford BackMedics’ anticancer vaccine ‘OVM-200,’ and advancing various new drug development projects including pipelines related to ophthalmic diseases, and the development of anticancer antibody vaccines and therapeutics through a dedicated new drug development organization.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
